Chapuis, Aude G. http://orcid.org/0000-0002-9574-5448
Egan, Daniel N.
Bar, Merav
Schmitt, Thomas M.
McAfee, Megan S.
Paulson, Kelly G.
Voillet, Valentin
Gottardo, Raphael
Ragnarsson, Gunnar B.
Bleakley, Marie
Yeung, Cecilia C.
Muhlhauser, Petri
Nguyen, Hieu N.
Kropp, Lara A.
Castelli, Luca
Wagener, Felecia
Hunter, Daniel
Lindberg, Marcus
Cohen, Kristen http://orcid.org/0000-0002-8901-9941
Seese, Aaron
McElrath, M. Juliana
Duerkopp, Natalie
Gooley, Ted A.
Greenberg, Philip D. http://orcid.org/0000-0003-3812-647X
Article History
Received: 23 October 2018
Revised: 23 April 2019
Accepted: 26 April 2019
First Online: 24 June 2019
Competing interests
: A.G.C. has received support from Juno Therapeutics. P.D.G. is a consultant, has received support from and had ownership interest in Juno Therapeutics. He consults and has ownership interest in Immune Design Corp, Innate Pharma and FLX Bio. P.D.G., T.M.S., H.N.N. and the Fred Hutchinson Cancer Research Center have intellectual property related to TCRC4. A.G.C. and K.G.P. have received reagents from 10X Genomics. R.G. has received consulting fees from Juno Therapeutics, Takeda Pharmaceuticals and Infotech Soft, and has received support from Johnson and Johnson and Juno Therapeutics. The authors declare no other competing interests.